Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for COVID-19 Induced Thrombotic Microangiopathy
NCT04570397Phase 3Unknown
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in coronavirus disease 2019 (COVID-19), thrombotic microangiopathy (TMA), acute kidney injury (AKI), sponsored by Brigham and Women's Hospital. Status: unknown.
02
Drugs
ravulizumab
03
Conditions
coronavirus disease 2019 (COVID-19)thrombotic microangiopathy (TMA)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04570397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570397.